{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"25"},{"groupId":"OG008","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"19"},{"groupId":"OG007","value":"68"},{"groupId":"OG008","value":"34"}],"units":"Participants"}],"description":"ORR was defined as the number of participants with a best overall response of complete response (CR) or partial response (PR) at the time each participant discontinued treatment with ADCT-402, before the start of subsequent anticancer therapy or procedure. Tumor response was assessed using the 2014 Lugano Classification for response.\n\nCR is defined as achieving either of the following:\n\n* Complete metabolic response.\n* Complete radiologic response (target node regress to \\<1.5 cm, no nonmeasured lesions, no organ enlargement, no new lesions and normal bone marrow morphology).\n\nPR is defined as achieving either of the following:\n\n* Partial metabolic response (findings indicate residual disease).\n* Partial remission (\\>50% decrease in target measurable nodes, regression/ absence/ no increase of nonmeasured lesions, spleen regressed by \\>50% in length and no new lesions).","groups":[{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG000","title":"Part 1: 15 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG001","title":"Part 1: 30 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG002","title":"Part 1: 60 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG003","title":"Part 1: 90 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG004","title":"Part 1: 120 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG005","title":"Part 2: 120 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG006","title":"Part 1: 150 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG007","title":"Part 2: 150 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Following protocol amendment 5, treatment cycle length was increased to 6 weeks (Q6W).","id":"OG008","title":"Part 1: 200 μg/kg Q3W and Q6W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one dose of study treatment with a valid baseline disease assessment and at least one valid post-baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"Baseline to End of Study (a maximum of 18 months)","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}